This bill mandates that medical care providers review FDA medication guides with the parent or guardian of a minor before prescribing psychotropic drugs under Medicaid. It introduces a new section, 167:3-n, to RSA 167, which defines "psychotropic drugs" and "medical care providers," and outlines the requirements for informed consent. Specifically, providers must print and review the FDA medication guide with the parent or guardian, detailing the risks, side effects, and adverse reactions associated with the medication. Written informed consent must be obtained from the parent or guardian prior to prescribing the drug, confirming their understanding of the information provided.

Additionally, the bill stipulates that medical care providers who do not comply with these requirements may face penalties, including suspension of Medicaid reimbursements, and must be reported to the board of medicine. The act is set to take effect on April 1, 2026. The bill does not include any deletions from current law but adds significant new provisions aimed at enhancing informed consent and accountability in the prescription of psychotropic medications for children under Medicaid.